Gene · 10
Papers3,552
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,552
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pharmacogenomic profiling of variants affecting efficacy and toxicity of anti-infective medicines in a south Asian population from Sri Lanka. | BMC Infect Dis | 2025 | 39893405 | PubTator, text mining | PubMed |
| Metabolic effects of heterocyclic amines on insulin‑induced AKT phosphorylation and gluconeogenic gene expression are modified by N -acetyltransferase 2 genetic polymorphism. | Pharmacogenet Genomics | 2025 | 39878101 | PubTator, text mining | PubMed |
| Pharmacokinetic Analysis of an Isoniazid Suspension Among Spanish Children Under 6 Years of Age. | Antibiotics (Basel) | 2025 | 39858360 | PubTator, text mining | PubMed |
| Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub-Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases. | Clin Pharmacol Ther | 2025 | 39829327 | PubTator, text mining | PubMed |
| NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study. | Clin Infect Dis | 2025 | 39727196 | PubTator, text mining | PubMed |
| The N-Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case-Control Study. | Pharmacol Res Perspect | 2025 | 39720855 | PubTator, text mining | PubMed |
| A study of N-acetyltransferase 2 gene polymorphisms in the Indian population and its relationship with serum isoniazid concentrations in a cohort of tuberculosis patients. | Monaldi Arch Chest Dis | 2025 | 39704240 | PubTator, text mining | PubMed |
| Artificial intelligence modeling of biomarker-based physiological age: Impact on phase 1 drug-metabolizing enzyme phenotypes. | CPT Pharmacometrics Syst Pharmacol | 2025 | 39540677 | PubTator, text mining | PubMed |
| The Potential of ESCO2 as a Prognostic and Immunotherapeutic Marker of Pan-Cancer and Its Role in Anti-PD-1 Treatment of Bladder Cancer. | Oncology | 2025 | 39527939 | PubTator, text mining | PubMed |
| Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort. | Pharmacogenet Genomics | 2025 | 39470346 | PubTator, text mining | PubMed |
| Arylamines N-acetyltransferases 1 and 2: physiology, genetics and epigenetics. | Gac Med Mex | 2024 | 40000435 | PubTator, text mining | PubMed |
| The role of isoniazid dosage and NAT2 gene polymorphism in the treatment of tuberculous meningitis. | Front Immunol | 2024 | 39902038 | PubTator, text mining | PubMed |
| Systematic Study of Steroid Drugs' Ability to Cross Biomembranes-The Possible Environmental Impact and Health Risks Associated with Exposure During Pregnancy. | Membranes (Basel) | 2024 | 39852245 | PubTator, text mining | PubMed |
| Effect of Genetic Variants on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Involvement of ABCG2, SLCO1B1 and NAT2. | Int J Mol Sci | 2024 | 39796117 | PubTator, text mining | PubMed |
Organic Sunscreens-Is Their Placenta Permeability the Only Issue Associated with Exposure During Pregnancy? In Silico Studies of Sunscreens' Placenta Permeability and Interactions with Selected Placental Enzymes. | Molecules | 2024 | 39769924 | PubTator, text mining | PubMed |
| Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol. | BMJ Open | 2024 | 39740953 | PubTator, text mining | PubMed |
| Pharmacogenomic landscape of the Thai population from genome sequencing of 949 individuals. | Sci Rep | 2024 | 39730427 | PubTator, text mining | PubMed |
| A pan-cancer analysis of the oncogenic role of N-acetyltransferase 8 like in human cancer. | Discov Oncol | 2024 | 39692770 | PubTator, text mining | PubMed |
| Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis. | BMC Genom Data | 2024 | 39639188 | PubTator, text mining | PubMed |
| Investigation on regulation of N-acetyltransferase 2 expression by nuclear receptors in human hepatocytes. | Front Pharmacol | 2024 | 39624836 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10/papers?page=6